메뉴 건너뛰기




Volumn 2, Issue 4, 2010, Pages 229-235

What is the role of maintenance therapy in the treatment of non-small cell lung cancer?

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PEMETREXED; PLACEBO;

EID: 78649314231     PISSN: 17588340     EISSN: None     Source Type: Journal    
DOI: 10.1177/1758834010368045     Document Type: Editorial
Times cited : (3)

References (36)
  • 1
    • 77649312646 scopus 로고    scopus 로고
    • (2010) Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population
    • Asukai, Y., Valladares, A., Camps, C., Wood, E., Taipale, K., Arellano, J. et al. (2010) Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population. BMC Cancer 10: 26.
    • BMC Cancer , vol.10 , pp. 26
    • Asukai, Y.1    Valladares, A.2    Camps, C.3    Wood, E.4    Taipale, K.5    Arellano, J.6
  • 2
    • 74949133978 scopus 로고    scopus 로고
    • American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for stage IV non-small cell lung cancer
    • Azzoli, C.G., Baker Jr, S., Temin, S., Pao, W., Aliff, T., Brahmer, J. et al. (2009) American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for stage IV non-small cell lung cancer. J Clin Oncol 27: 6251-6266.
    • (2009) J Clin Oncol , vol.27 , pp. 6251-6266
    • Azzoli, C.G.1    Baker Jr, S.2    Temin, S.3    Pao, W.4    Aliff, T.5    Brahmer, J.6
  • 3
    • 25444511051 scopus 로고    scopus 로고
    • Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer
    • Belani, C.P., Lee, J.S., Socinski, M.A., Robert, F., Waterhouse, D., Rowland, K. et al. (2005) Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 16: 1069-1075.
    • (2005) Ann Oncol , vol.16 , pp. 1069-1075
    • Belani, C.P.1    Lee, J.S.2    Socinski, M.A.3    Robert, F.4    Waterhouse, D.5    Rowland, K.6
  • 4
    • 33646485007 scopus 로고    scopus 로고
    • Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial
    • Brodowicz, T., Krzakowski, M., Zwitter, M., Tzekova, V., Ramlau, R., Ghilezan, N. et al. (2006) Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 52: 155-163.
    • (2006) Lung Cancer , vol.52 , pp. 155-163
    • Brodowicz, T.1    Krzakowski, M.2    Zwitter, M.3    Tzekova, V.4    Ramlau, R.5    Ghilezan, N.6
  • 5
    • 70349475409 scopus 로고    scopus 로고
    • SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC
    • et al., on behalf of the SATURN Investigators (Suppl): Abstract
    • Cappuzzo, F.C.T., Stelmakh, L., Cicenas, S., Szczesna, A., Juhasz, E. and Esteban Gonzalez, E. et al., on behalf of the SATURN Investigators ( 2009) SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 27(Suppl): Abstract 8001.
    • (2009) J Clin Oncol , vol.27 , pp. 8001
    • Cappuzzo, F.C.T.1    Stelmakh, L.2    Cicenas, S.3    Szczesna, A.4    Juhasz, E.5    Esteban Gonzalez, E.6
  • 6
    • 50849117805 scopus 로고    scopus 로고
    • Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC)
    • Carlson, J.J., Reyes, C., Oestreicher, N., Lubeck, D., Ramsey, S.D. and Veenstra, D.L. ( 2008) Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer 61: 405-415.
    • (2008) Lung Cancer , vol.61 , pp. 405-415
    • Carlson, J.J.1    Reyes, C.2    Oestreicher, N.3    Lubeck, D.4    Ramsey, S.D.5    Veenstra, D.L.6
  • 7
    • 70350225538 scopus 로고    scopus 로고
    • (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small cell lung cancer: a randomised, double-blind, phase 3 study
    • Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J.H., Krzakowski, M., Laack, E. et al. (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374: 1432-1440.
    • Lancet , vol.374 , pp. 1432-1440
    • Ciuleanu, T.1    Brodowicz, T.2    Zielinski, C.3    Kim, J.H.4    Krzakowski, M.5    Laack, E.6
  • 8
    • 77649222572 scopus 로고    scopus 로고
    • (2010) Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small cell lung cancer: data from the randomized phase III INTEREST trial
    • Douillard, J.Y., Shepherd, F.A., Hirsh, V., Mok, T., Socinski, M.A., Gervais, R. et al. (2010) Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 28: 744-752.
    • J Clin Oncol , vol.28 , pp. 744-752
    • Douillard, J.Y.1    Shepherd, F.A.2    Hirsh, V.3    Mok, T.4    Socinski, M.A.5    Gervais, R.6
  • 9
    • 59149092945 scopus 로고    scopus 로고
    • (2009) Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer
    • Fidias, P.M., Dakhil, S.R., Lyss, A.P., Loesch, D.M., Waterhouse, D.M., Bromund, J.L. et al. (2009) Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol 27: 591-598.
    • J Clin Oncol , vol.27 , pp. 591-598
    • Fidias, P.M.1    Dakhil, S.R.2    Lyss, A.P.3    Loesch, D.M.4    Waterhouse, D.M.5    Bromund, J.L.6
  • 10
    • 68249134187 scopus 로고    scopus 로고
    • (2009) How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question
    • Fojo, T. and Grady, C. (2009) How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 101: 1044-1048.
    • J Natl Cancer Inst , vol.101 , pp. 1044-1048
    • Fojo, T.1    Grady, C.2
  • 11
    • 0042413836 scopus 로고    scopus 로고
    • Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group
    • Fossella, F., Pereira, J.R., von Pawel, J., Pluzanska, A., Gorbounova, V., Kaukel, E. et al. (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group. J Clin Oncol 21: 3016-3024.
    • (2003) J Clin Oncol , vol.21 , pp. 3016-3024
    • Fossella, F.1    Pereira, J.R.2    von Pawel, J.3    Pluzanska, A.4    Gorbounova, V.5    Kaukel, E.6
  • 12
    • 2442661845 scopus 로고    scopus 로고
    • (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy
    • Hanna, N., Shepherd, F.A., Fossella, F.V., Pereira, J.R., de Marinis, F., von Pawel, J. et al. (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597.
    • J Clin Oncol , vol.22 , pp. 1589-1597
    • Hanna, N.1    Shepherd, F.A.2    Fossella, F.V.3    Pereira, J.R.4    de Marinis, F.5    von Pawel, J.6
  • 13
    • 56249109644 scopus 로고    scopus 로고
    • Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomised phase III trial
    • Kim, E.S., Hirsh, V., Mok, T., Socinski, M.A., Gervais, R., Wu, Y.L. et al. (2008) Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372: 1809-1818.
    • (2008) Lancet , vol.372 , pp. 1809-1818
    • Kim, E.S.1    Hirsh, V.2    Mok, T.3    Socinski, M.A.4    Gervais, R.5    Wu, Y.L.6
  • 15
    • 73449117924 scopus 로고    scopus 로고
    • (2010) Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer
    • Lyseng-Williamson, K.A. (2010) Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer. Pharmaco Economics 28: 75-92.
    • Pharmaco Economics , vol.28 , pp. 75-92
    • Lyseng-Williamson, K.A.1
  • 16
    • 19944413630 scopus 로고    scopus 로고
    • Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer
    • Martoni, A., Marino, A., Sperandi, F., Giaquinta, S., Di Fabio, F., Melotti, B. et al. (2005) Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 41: 81-92.
    • (2005) Eur J Cancer , vol.41 , pp. 81-92
    • Martoni, A.1    Marino, A.2    Sperandi, F.3    Giaquinta, S.4    Di Fabio, F.5    Melotti, B.6
  • 17
    • 70349477817 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
    • and for the ATLAS Investigators Abstract LBA8002.
    • Miller, V.A.O.C.P., Soh, C., Kabbinavar, F., and for the ATLAS Investigators ( 2009) A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 27: Abstract LBA8002.
    • (2009) J Clin Oncol , vol.27
    • Miller, V.A.O.C.P.1    Soh, C.2    Kabbinavar, F.3
  • 18
  • 19
    • 84971581087 scopus 로고
    • Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
    • Non-small Cell Lung Cancer Collaborative Group
    • Non-small Cell Lung Cancer Collaborative Group ( 1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909.
    • (1995) BMJ , vol.311 , pp. 899-909
  • 21
    • 36849019938 scopus 로고    scopus 로고
    • Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small cell lung cancer
    • Park, J.O., Kim, S.W., Ahn, J.S., Suh, C., Lee, J.S., Jang, J.S. et al. (2007) Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small cell lung cancer. J Clin Oncol 25: 5233-5239.
    • (2007) J Clin Oncol , vol.25 , pp. 5233-5239
    • Park, J.O.1    Kim, S.W.2    Ahn, J.S.3    Suh, C.4    Lee, J.S.5    Jang, J.S.6
  • 22
    • 1342268525 scopus 로고    scopus 로고
    • American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003
    • Pfister, D.G., Johnson, D.H., Azzoli, C.G., Sause, W., Smith, T.J., Baker Jr, S. et al. (2004) American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 22: 330-353.
    • (2004) J Clin Oncol , vol.22 , pp. 330-353
    • Pfister, D.G.1    Johnson, D.H.2    Azzoli, C.G.3    Sause, W.4    Smith, T.J.5    Baker Jr, S.6
  • 23
    • 62449124416 scopus 로고    scopus 로고
    • Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAil
    • Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V. et al. (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAil. J Clin Oncol 27: 1227-1234.
    • (2009) J Clin Oncol , vol.27 , pp. 1227-1234
    • Reck, M.1    von Pawel, J.2    Zatloukal, P.3    Ramlau, R.4    Gorbounova, V.5    Hirsh, V.6
  • 24
    • 69949186250 scopus 로고    scopus 로고
    • (2009) Screening for epidermal growth factor receptor mutations in lung cancer
    • Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C. et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967.
    • N Engl J Med , vol.361 , pp. 958-967
    • Rosell, R.1    Moran, T.2    Queralt, C.3    Porta, R.4    Cardenal, F.5    Camps, C.6
  • 25
    • 16644398719 scopus 로고    scopus 로고
    • Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small cell lung cancer: a phase III randomized study of the London Lung Cancer Group
    • Rudd, R.M., Gower, N.H., Spiro, S.G., Eisen, T.G., Harper, P.G., Littler, J.A. et al. (2005) Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 23: 142-153.
    • (2005) J Clin Oncol , vol.23 , pp. 142-153
    • Rudd, R.M.1    Gower, N.H.2    Spiro, S.G.3    Eisen, T.G.4    Harper, P.G.5    Littler, J.A.6
  • 26
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer
    • Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A. et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355: 2542-2550.
    • (2006) N Engl J Med , vol.355 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3    Brahmer, J.4    Schiller, J.H.5    Dowlati, A.6
  • 27
    • 64049115311 scopus 로고    scopus 로고
    • (2009) The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies
    • Scagliotti, G., Hanna, N., Fossella, F., Sugarman, K., Blatter, J., Peterson, P. et al. (2009) The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14: 253-263.
    • Oncologist , vol.14 , pp. 253-263
    • Scagliotti, G.1    Hanna, N.2    Fossella, F.3    Sugarman, K.4    Blatter, J.5    Peterson, P.6
  • 28
    • 0036843105 scopus 로고    scopus 로고
    • Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer
    • Scagliotti, G.V., de Marinis, F., Rinaldi, M., Crino, L., Gridelli, C., Ricci, S. et al. (2002) Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 20: 4285-4291.
    • (2002) J Clin Oncol , vol.20 , pp. 4285-4291
    • Scagliotti, G.V.1    de Marinis, F.2    Rinaldi, M.3    Crino, L.4    Gridelli, C.5    Ricci, S.6
  • 29
    • 49049089802 scopus 로고    scopus 로고
    • (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer
    • Scagliotti, G.V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C. et al. (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol 26: 3543-3551.
    • J Clin Oncol , vol.26 , pp. 3543-3551
    • Scagliotti, G.V.1    Parikh, P.2    von Pawel, J.3    Biesma, B.4    Vansteenkiste, J.5    Manegold, C.6
  • 30
    • 33644684204 scopus 로고    scopus 로고
    • Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small cell lung cancer: the Swedish Lung Cancer Study Group
    • Sederholm, C., Hillerdal, G., Lamberg, K., Kolbeck, K., Dufmats, M., Westberg, R. et al. (2005) Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 23: 8380-8388.
    • (2005) J Clin Oncol , vol.23 , pp. 8380-8388
    • Sederholm, C.1    Hillerdal, G.2    Lamberg, K.3    Kolbeck, K.4    Dufmats, M.5    Westberg, R.6
  • 32
    • 0036499649 scopus 로고    scopus 로고
    • Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB / IV non-small cell lung cancer
    • Socinski, M.A., Schell, M.J., Peterman, A., Bakri, K., Yates, S., Gitten, R. et al. (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB / IV non-small cell lung cancer. J Clin Oncol 20: 1335-1343.
    • (2002) J Clin Oncol , vol.20 , pp. 1335-1343
    • Socinski, M.A.1    Schell, M.J.2    Peterman, A.3    Bakri, K.4    Yates, S.5    Gitten, R.6
  • 33
    • 70249130544 scopus 로고    scopus 로고
    • (2009) Duration of chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized trials
    • Soon, Y.Y., Stockler, M.R., Askie, L.M. and Boyer, M.J. (2009) Duration of chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 27: 3277-3283.
    • J Clin Oncol , vol.27 , pp. 3277-3283
    • Soon, Y.Y.1    Stockler, M.R.2    Askie, L.M.3    Boyer, M.J.4
  • 34
    • 22044453790 scopus 로고    scopus 로고
    • Erlotinib in lung cancer - molecular and clinical predictors of outcome
    • Tsao, M.S., Sakurada, A., Cutz, J.C., Zhu, C.Q., Kamel-Reid, S., Squire, J. et al. (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353: 133-144.
    • (2005) N Engl J Med , vol.353 , pp. 133-144
    • Tsao, M.S.1    Sakurada, A.2    Cutz, J.C.3    Zhu, C.Q.4    Kamel-Reid, S.5    Squire, J.6
  • 35
    • 33750207905 scopus 로고    scopus 로고
    • (2006) Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small cell lung cancer
    • von Plessen, C., Bergman, B., Andresen, O., Bremnes, R.M., Sundstrom, S., Gilleryd, M. et al. (2006) Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small cell lung cancer. Br J Cancer 95: 966-973.
    • Br J Cancer , vol.95 , pp. 966-973
    • von Plessen, C.1    Bergman, B.2    Andresen, O.3    Bremnes, R.M.4    Sundstrom, S.5    Gilleryd, M.6
  • 36
    • 15944388587 scopus 로고    scopus 로고
    • Randomized study of maintenance vinorelbine in responders with advanced non-small cell lung cancer
    • Westeel, V., Quoix, E., Moro-Sibilot, D., Mercier, M., Breton, J.L., Debieuvre, D. et al. (2005) Randomized study of maintenance vinorelbine in responders with advanced non-small cell lung cancer. J Natl Cancer Inst 97: 499-506.
    • (2005) J Natl Cancer Inst , vol.97 , pp. 499-506
    • Westeel, V.1    Quoix, E.2    Moro-Sibilot, D.3    Mercier, M.4    Breton, J.L.5    Debieuvre, D.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.